| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Suicide | 25 | 2023 | 139 | 8.300 |
Why?
|
| Suicide, Attempted | 24 | 2024 | 129 | 6.880 |
Why?
|
| Diagnosis, Computer-Assisted | 19 | 2021 | 332 | 6.330 |
Why?
|
| Bipolar Disorder | 21 | 2022 | 377 | 5.900 |
Why?
|
| Depressive Disorder | 40 | 2019 | 218 | 5.640 |
Why?
|
| Depressive Disorder, Major | 15 | 2022 | 158 | 4.660 |
Why?
|
| Dengue | 33 | 2019 | 43 | 4.350 |
Why?
|
| Psychotic Disorders | 10 | 2023 | 184 | 4.210 |
Why?
|
| Dengue Virus | 30 | 2019 | 41 | 3.770 |
Why?
|
| Self-Injurious Behavior | 6 | 2023 | 105 | 3.710 |
Why?
|
| Mental Disorders | 27 | 2020 | 371 | 3.590 |
Why?
|
| Randomized Controlled Trials as Topic | 21 | 2023 | 865 | 3.530 |
Why?
|
| Psychiatric Status Rating Scales | 32 | 2024 | 487 | 3.130 |
Why?
|
| Psychometrics | 18 | 2022 | 327 | 3.110 |
Why?
|
| Schizophrenia | 19 | 2022 | 464 | 2.860 |
Why?
|
| Depression | 18 | 2023 | 473 | 2.720 |
Why?
|
| Anxiety Disorders | 9 | 2022 | 148 | 2.570 |
Why?
|
| Adolescent | 102 | 2024 | 8984 | 2.450 |
Why?
|
| Substance-Related Disorders | 10 | 2024 | 394 | 2.420 |
Why?
|
| Humans | 291 | 2024 | 86678 | 2.320 |
Why?
|
| Antidepressive Agents | 14 | 2021 | 106 | 2.100 |
Why?
|
| Veterans | 5 | 2022 | 72 | 2.020 |
Why?
|
| Adult | 119 | 2024 | 25659 | 1.980 |
Why?
|
| Male | 171 | 2022 | 40988 | 1.900 |
Why?
|
| Female | 171 | 2023 | 44550 | 1.850 |
Why?
|
| Anxiety | 10 | 2023 | 287 | 1.850 |
Why?
|
| Personality Inventory | 9 | 2014 | 108 | 1.840 |
Why?
|
| Fluoxetine | 5 | 2015 | 42 | 1.840 |
Why?
|
| Cyclohexanols | 4 | 2013 | 7 | 1.770 |
Why?
|
| Longitudinal Studies | 25 | 2022 | 1019 | 1.700 |
Why?
|
| Models, Statistical | 18 | 2017 | 575 | 1.700 |
Why?
|
| Antibodies, Viral | 23 | 2019 | 293 | 1.690 |
Why?
|
| Analgesics, Opioid | 8 | 2022 | 413 | 1.640 |
Why?
|
| United States | 57 | 2023 | 6681 | 1.580 |
Why?
|
| Child | 81 | 2023 | 6928 | 1.560 |
Why?
|
| Suicidal Ideation | 9 | 2023 | 67 | 1.550 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 12 | 2019 | 183 | 1.460 |
Why?
|
| Young Adult | 43 | 2022 | 5980 | 1.410 |
Why?
|
| Anticonvulsants | 4 | 2010 | 126 | 1.390 |
Why?
|
| Models, Psychological | 8 | 2022 | 157 | 1.380 |
Why?
|
| Drug Prescriptions | 10 | 2019 | 141 | 1.330 |
Why?
|
| Regression Analysis | 21 | 2017 | 596 | 1.310 |
Why?
|
| Middle Aged | 84 | 2022 | 25040 | 1.300 |
Why?
|
| Research Design | 16 | 2022 | 594 | 1.280 |
Why?
|
| Sexual and Gender Minorities | 2 | 2021 | 192 | 1.250 |
Why?
|
| Antipsychotic Agents | 5 | 2023 | 123 | 1.250 |
Why?
|
| Reproducibility of Results | 18 | 2021 | 2706 | 1.230 |
Why?
|
| Influenza, Human | 11 | 2018 | 329 | 1.200 |
Why?
|
| Thailand | 35 | 2019 | 66 | 1.200 |
Why?
|
| Central Nervous System Stimulants | 9 | 2019 | 216 | 1.150 |
Why?
|
| Data Interpretation, Statistical | 7 | 2017 | 297 | 1.130 |
Why?
|
| Cluster Analysis | 17 | 2022 | 369 | 1.110 |
Why?
|
| Observational Studies as Topic | 3 | 2023 | 48 | 1.080 |
Why?
|
| Tissue and Organ Procurement | 6 | 2021 | 311 | 1.040 |
Why?
|
| Child, Preschool | 47 | 2019 | 3613 | 1.030 |
Why?
|
| Severe Dengue | 8 | 2016 | 8 | 1.020 |
Why?
|
| Lithium Compounds | 2 | 2018 | 8 | 1.020 |
Why?
|
| Drug Overdose | 3 | 2022 | 65 | 1.020 |
Why?
|
| Alprazolam | 1 | 2024 | 4 | 0.970 |
Why?
|
| Mass Screening | 7 | 2021 | 619 | 0.970 |
Why?
|
| Anti-Anxiety Agents | 1 | 2024 | 23 | 0.970 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 7 | 2018 | 102 | 0.970 |
Why?
|
| Outpatients | 4 | 2021 | 94 | 0.940 |
Why?
|
| Cannabis | 1 | 2024 | 34 | 0.930 |
Why?
|
| Psychological Tests | 3 | 2014 | 91 | 0.930 |
Why?
|
| Risk Factors | 27 | 2023 | 5420 | 0.920 |
Why?
|
| Evidence-Based Practice | 5 | 2016 | 45 | 0.920 |
Why?
|
| Meta-Analysis as Topic | 5 | 2015 | 87 | 0.880 |
Why?
|
| Computer Simulation | 5 | 2020 | 1078 | 0.880 |
Why?
|
| Encephalitis, Japanese | 6 | 2015 | 6 | 0.870 |
Why?
|
| Cohort Studies | 25 | 2023 | 2768 | 0.840 |
Why?
|
| Mental Health | 3 | 2019 | 162 | 0.810 |
Why?
|
| Vitamin D Deficiency | 1 | 2022 | 103 | 0.810 |
Why?
|
| Stress Disorders, Post-Traumatic | 2 | 2021 | 96 | 0.800 |
Why?
|
| Lung Transplantation | 3 | 2016 | 175 | 0.800 |
Why?
|
| Aged | 46 | 2022 | 18423 | 0.790 |
Why?
|
| Treatment Outcome | 26 | 2023 | 7998 | 0.790 |
Why?
|
| Heart Transplantation | 5 | 2021 | 705 | 0.780 |
Why?
|
| Sample Size | 2 | 2013 | 130 | 0.730 |
Why?
|
| Adolescent Behavior | 2 | 2019 | 106 | 0.720 |
Why?
|
| Parents | 2 | 2020 | 272 | 0.720 |
Why?
|
| Antidepressive Agents, Second-Generation | 3 | 2015 | 19 | 0.720 |
Why?
|
| Child of Impaired Parents | 1 | 2019 | 19 | 0.710 |
Why?
|
| Infant | 30 | 2023 | 3047 | 0.700 |
Why?
|
| Cross-Sectional Studies | 14 | 2019 | 1621 | 0.700 |
Why?
|
| Waiting Lists | 4 | 2021 | 175 | 0.700 |
Why?
|
| Pressure Ulcer | 2 | 2017 | 42 | 0.690 |
Why?
|
| Encephalitis Virus, Japanese | 5 | 2015 | 6 | 0.690 |
Why?
|
| Child Behavior | 1 | 2019 | 48 | 0.680 |
Why?
|
| Prisoners | 1 | 2019 | 40 | 0.680 |
Why?
|
| Neocortex | 1 | 2020 | 95 | 0.680 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2015 | 199 | 0.670 |
Why?
|
| Hospitals, Psychiatric | 4 | 2017 | 22 | 0.660 |
Why?
|
| Psychotherapy | 6 | 2023 | 74 | 0.660 |
Why?
|
| Surveys and Questionnaires | 10 | 2021 | 2504 | 0.660 |
Why?
|
| Transients and Migrants | 1 | 2018 | 6 | 0.650 |
Why?
|
| Groundwater | 1 | 2018 | 10 | 0.650 |
Why?
|
| Poisson Distribution | 4 | 2014 | 51 | 0.630 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2017 | 3 | 0.620 |
Why?
|
| Hospitals, General | 1 | 2017 | 12 | 0.620 |
Why?
|
| Emigrants and Immigrants | 1 | 2018 | 44 | 0.610 |
Why?
|
| Hospital Bed Capacity | 1 | 2017 | 20 | 0.610 |
Why?
|
| Risk Assessment | 9 | 2023 | 2264 | 0.610 |
Why?
|
| Dengue Vaccines | 6 | 2019 | 6 | 0.610 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 3 | 2018 | 80 | 0.610 |
Why?
|
| Emergency Service, Hospital | 6 | 2023 | 484 | 0.580 |
Why?
|
| Deep Brain Stimulation | 1 | 2017 | 54 | 0.580 |
Why?
|
| Smoking Cessation | 4 | 2017 | 230 | 0.570 |
Why?
|
| Reoperation | 3 | 2009 | 597 | 0.570 |
Why?
|
| Dementia | 1 | 2018 | 187 | 0.570 |
Why?
|
| Logistic Models | 15 | 2017 | 1188 | 0.560 |
Why?
|
| Cancer Survivors | 1 | 2017 | 85 | 0.550 |
Why?
|
| Behavior Therapy | 7 | 2013 | 75 | 0.540 |
Why?
|
| Statistics as Topic | 10 | 2017 | 238 | 0.540 |
Why?
|
| Population Surveillance | 5 | 2015 | 219 | 0.540 |
Why?
|
| Tissue Donors | 3 | 2016 | 464 | 0.530 |
Why?
|
| Incidence | 14 | 2017 | 1578 | 0.520 |
Why?
|
| Severity of Illness Index | 14 | 2019 | 1802 | 0.520 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 3 | 2011 | 22 | 0.510 |
Why?
|
| Prescriptions | 4 | 2022 | 21 | 0.510 |
Why?
|
| Leukotriene Antagonists | 2 | 2012 | 25 | 0.510 |
Why?
|
| Biometry | 5 | 2007 | 66 | 0.500 |
Why?
|
| Sensitivity and Specificity | 15 | 2021 | 1992 | 0.500 |
Why?
|
| Waste Management | 1 | 2014 | 4 | 0.500 |
Why?
|
| Hospitalization | 12 | 2020 | 851 | 0.500 |
Why?
|
| Water Pollution, Chemical | 1 | 2014 | 21 | 0.490 |
Why?
|
| Bartonella Infections | 2 | 2011 | 5 | 0.490 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 380 | 0.490 |
Why?
|
| Bartonella | 2 | 2011 | 6 | 0.490 |
Why?
|
| Prospective Studies | 22 | 2023 | 4214 | 0.490 |
Why?
|
| Opioid-Related Disorders | 4 | 2022 | 161 | 0.490 |
Why?
|
| Military Personnel | 4 | 2022 | 85 | 0.490 |
Why?
|
| RNA, Viral | 9 | 2018 | 329 | 0.480 |
Why?
|
| Sentinel Surveillance | 2 | 2018 | 23 | 0.480 |
Why?
|
| Social Control Policies | 1 | 2013 | 2 | 0.470 |
Why?
|
| Rabies | 2 | 2004 | 7 | 0.470 |
Why?
|
| Quinoxalines | 1 | 2013 | 50 | 0.470 |
Why?
|
| Benzazepines | 1 | 2013 | 89 | 0.450 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 408 | 0.450 |
Why?
|
| Antigens, Viral | 5 | 2015 | 143 | 0.450 |
Why?
|
| Autistic Disorder | 1 | 2014 | 147 | 0.440 |
Why?
|
| Water Pollutants, Chemical | 1 | 2014 | 135 | 0.440 |
Why?
|
| Aged, 80 and over | 16 | 2018 | 6513 | 0.440 |
Why?
|
| Odds Ratio | 9 | 2020 | 680 | 0.440 |
Why?
|
| Intellectual Disability | 1 | 2014 | 186 | 0.440 |
Why?
|
| Psychiatry | 3 | 2011 | 78 | 0.440 |
Why?
|
| Firearms | 1 | 2013 | 49 | 0.440 |
Why?
|
| Antibodies, Neutralizing | 5 | 2015 | 112 | 0.430 |
Why?
|
| Benzodiazepines | 2 | 2024 | 65 | 0.430 |
Why?
|
| Primary Health Care | 6 | 2023 | 339 | 0.430 |
Why?
|
| Biostatistics | 1 | 2012 | 20 | 0.420 |
Why?
|
| Mood Disorders | 9 | 2017 | 81 | 0.420 |
Why?
|
| Quality Improvement | 1 | 2016 | 429 | 0.420 |
Why?
|
| Tachycardia | 1 | 2012 | 35 | 0.420 |
Why?
|
| Heart-Assist Devices | 2 | 2010 | 731 | 0.410 |
Why?
|
| Databases, Factual | 7 | 2020 | 816 | 0.410 |
Why?
|
| Immunoglobulin M | 3 | 2012 | 154 | 0.410 |
Why?
|
| Decision Making | 2 | 2016 | 642 | 0.400 |
Why?
|
| Bayes Theorem | 5 | 2023 | 361 | 0.390 |
Why?
|
| Feedback, Psychological | 1 | 2011 | 18 | 0.390 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2010 | 17 | 0.390 |
Why?
|
| Electronic Health Records | 4 | 2022 | 320 | 0.390 |
Why?
|
| Pandemics | 5 | 2022 | 740 | 0.380 |
Why?
|
| Amines | 1 | 2010 | 27 | 0.380 |
Why?
|
| Time Factors | 17 | 2020 | 5214 | 0.380 |
Why?
|
| United States Food and Drug Administration | 6 | 2012 | 127 | 0.380 |
Why?
|
| Retrospective Studies | 19 | 2022 | 8496 | 0.380 |
Why?
|
| Quality of Life | 2 | 2022 | 1585 | 0.380 |
Why?
|
| Multicenter Studies as Topic | 4 | 2007 | 159 | 0.380 |
Why?
|
| Liver Transplantation | 4 | 2004 | 1271 | 0.380 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2010 | 83 | 0.370 |
Why?
|
| Vaccination | 7 | 2022 | 254 | 0.370 |
Why?
|
| Spain | 3 | 2020 | 33 | 0.370 |
Why?
|
| Psychology, Clinical | 1 | 2010 | 6 | 0.370 |
Why?
|
| Follow-Up Studies | 20 | 2021 | 3642 | 0.370 |
Why?
|
| Cause of Death | 2 | 2009 | 277 | 0.370 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 3362 | 0.360 |
Why?
|
| Biomedical Research | 1 | 2014 | 376 | 0.360 |
Why?
|
| Drug Approval | 2 | 2010 | 62 | 0.360 |
Why?
|
| Age Factors | 13 | 2014 | 1852 | 0.360 |
Why?
|
| Health Care Rationing | 2 | 2016 | 83 | 0.350 |
Why?
|
| Machine Learning | 2 | 2022 | 232 | 0.350 |
Why?
|
| Heart Rate | 1 | 2012 | 492 | 0.350 |
Why?
|
| Accidents, Traffic | 2 | 2022 | 94 | 0.340 |
Why?
|
| Demography | 1 | 2009 | 177 | 0.340 |
Why?
|
| Empathy | 1 | 2011 | 147 | 0.340 |
Why?
|
| Heart-Lung Transplantation | 1 | 2008 | 17 | 0.340 |
Why?
|
| Product Surveillance, Postmarketing | 2 | 2008 | 37 | 0.330 |
Why?
|
| Prosthesis-Related Infections | 1 | 2009 | 58 | 0.330 |
Why?
|
| Hepatitis E virus | 3 | 2013 | 6 | 0.330 |
Why?
|
| Prevalence | 9 | 2019 | 1239 | 0.330 |
Why?
|
| Mammals | 1 | 2010 | 227 | 0.330 |
Why?
|
| Models, Theoretical | 4 | 2009 | 482 | 0.330 |
Why?
|
| Hepatitis E | 3 | 2013 | 9 | 0.320 |
Why?
|
| Phenotype | 5 | 2020 | 2380 | 0.320 |
Why?
|
| Crisis Intervention | 1 | 2007 | 7 | 0.310 |
Why?
|
| Sex Factors | 11 | 2017 | 1055 | 0.310 |
Why?
|
| Rabies Vaccines | 2 | 2004 | 7 | 0.310 |
Why?
|
| Bites and Stings | 2 | 2004 | 9 | 0.310 |
Why?
|
| Organ Transplantation | 2 | 2003 | 265 | 0.310 |
Why?
|
| Minority Groups | 2 | 2023 | 137 | 0.310 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 5 | 2013 | 46 | 0.310 |
Why?
|
| Patient Dropouts | 1 | 2007 | 28 | 0.310 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2007 | 26 | 0.310 |
Why?
|
| Preoperative Care | 1 | 2010 | 397 | 0.300 |
Why?
|
| Multivariate Analysis | 7 | 2015 | 1001 | 0.300 |
Why?
|
| Blood Pressure | 2 | 2016 | 1144 | 0.300 |
Why?
|
| Program Development | 1 | 2007 | 125 | 0.300 |
Why?
|
| Serotyping | 7 | 2015 | 28 | 0.300 |
Why?
|
| Genetic Variation | 2 | 2011 | 1351 | 0.300 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 4 | 2022 | 216 | 0.290 |
Why?
|
| Medical Records | 1 | 2007 | 119 | 0.290 |
Why?
|
| Pharmacoepidemiology | 3 | 2011 | 6 | 0.290 |
Why?
|
| Insurance, Health | 4 | 2022 | 160 | 0.290 |
Why?
|
| Nepal | 6 | 2013 | 14 | 0.290 |
Why?
|
| Influenza Vaccines | 3 | 2018 | 142 | 0.280 |
Why?
|
| Drug Utilization | 4 | 2018 | 65 | 0.280 |
Why?
|
| Cognition | 2 | 2023 | 571 | 0.280 |
Why?
|
| Graft Rejection | 2 | 2009 | 1065 | 0.280 |
Why?
|
| Pain Management | 2 | 2018 | 127 | 0.280 |
Why?
|
| Pregnancy | 6 | 2022 | 2894 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 7 | 2012 | 376 | 0.270 |
Why?
|
| Community Mental Health Services | 5 | 2012 | 15 | 0.270 |
Why?
|
| Patient Selection | 4 | 2016 | 686 | 0.270 |
Why?
|
| Genotype | 5 | 2016 | 1852 | 0.270 |
Why?
|
| Sexual Behavior | 4 | 2021 | 302 | 0.260 |
Why?
|
| Asymptomatic Infections | 4 | 2014 | 16 | 0.260 |
Why?
|
| Disease Outbreaks | 5 | 2015 | 154 | 0.260 |
Why?
|
| Child Behavior Disorders | 3 | 2004 | 76 | 0.260 |
Why?
|
| Chiroptera | 2 | 2004 | 51 | 0.260 |
Why?
|
| Infant, Newborn | 9 | 2018 | 2379 | 0.260 |
Why?
|
| Propensity Score | 2 | 2019 | 136 | 0.260 |
Why?
|
| Risk | 10 | 2019 | 674 | 0.260 |
Why?
|
| Biomarkers | 4 | 2022 | 1718 | 0.250 |
Why?
|
| Likelihood Functions | 4 | 2014 | 251 | 0.250 |
Why?
|
| Buspirone | 1 | 2024 | 1 | 0.250 |
Why?
|
| Age Distribution | 5 | 2017 | 204 | 0.250 |
Why?
|
| Lorazepam | 1 | 2024 | 16 | 0.240 |
Why?
|
| Diazepam | 1 | 2024 | 28 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2011 | 861 | 0.240 |
Why?
|
| Rural Population | 9 | 2014 | 136 | 0.240 |
Why?
|
| Illinois | 4 | 2022 | 462 | 0.240 |
Why?
|
| Hallucinations | 1 | 2023 | 27 | 0.230 |
Why?
|
| Health Education | 2 | 2002 | 101 | 0.230 |
Why?
|
| Thinking | 1 | 2023 | 33 | 0.230 |
Why?
|
| Brain | 3 | 2020 | 2216 | 0.230 |
Why?
|
| Benztropine | 1 | 2023 | 4 | 0.230 |
Why?
|
| Patient Portals | 1 | 2023 | 15 | 0.230 |
Why?
|
| Comorbidity | 5 | 2019 | 944 | 0.230 |
Why?
|
| Citalopram | 2 | 2015 | 20 | 0.230 |
Why?
|
| Environmental Exposure | 2 | 2003 | 296 | 0.220 |
Why?
|
| Case-Control Studies | 10 | 2017 | 1807 | 0.220 |
Why?
|
| Cytokines | 3 | 2019 | 778 | 0.220 |
Why?
|
| Support Vector Machine | 1 | 2022 | 25 | 0.220 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 2 | 2015 | 45 | 0.220 |
Why?
|
| Self Report | 3 | 2020 | 288 | 0.220 |
Why?
|
| Reagent Kits, Diagnostic | 3 | 2012 | 39 | 0.220 |
Why?
|
| Vitamin B 12 | 1 | 2022 | 24 | 0.220 |
Why?
|
| Cholecalciferol | 1 | 2022 | 35 | 0.220 |
Why?
|
| Resource Allocation | 2 | 2019 | 65 | 0.220 |
Why?
|
| Insurance Claim Review | 3 | 2014 | 41 | 0.220 |
Why?
|
| Venlafaxine Hydrochloride | 2 | 2012 | 4 | 0.220 |
Why?
|
| Insect Vectors | 2 | 2015 | 9 | 0.220 |
Why?
|
| Hemodynamics | 2 | 2016 | 711 | 0.220 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 1566 | 0.220 |
Why?
|
| Triage | 1 | 2023 | 108 | 0.220 |
Why?
|
| Folic Acid | 1 | 2022 | 60 | 0.220 |
Why?
|
| Recreation | 1 | 2002 | 7 | 0.220 |
Why?
|
| Physicians | 4 | 2018 | 674 | 0.210 |
Why?
|
| Algorithms | 9 | 2016 | 1830 | 0.210 |
Why?
|
| Population Health | 1 | 2022 | 33 | 0.210 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2019 | 50 | 0.210 |
Why?
|
| Vitamins | 1 | 2022 | 81 | 0.210 |
Why?
|
| Hepatitis Antibodies | 2 | 2012 | 6 | 0.210 |
Why?
|
| Pain | 3 | 2022 | 391 | 0.210 |
Why?
|
| Dietary Supplements | 1 | 2022 | 128 | 0.210 |
Why?
|
| Software | 2 | 1996 | 654 | 0.210 |
Why?
|
| Neuropsychological Tests | 2 | 2021 | 502 | 0.200 |
Why?
|
| Antimanic Agents | 1 | 2001 | 11 | 0.200 |
Why?
|
| Heterosexuality | 1 | 2021 | 17 | 0.200 |
Why?
|
| Public Health | 1 | 2022 | 129 | 0.200 |
Why?
|
| Ethanol | 1 | 2024 | 249 | 0.200 |
Why?
|
| Depression, Postpartum | 1 | 2021 | 14 | 0.200 |
Why?
|
| Aripiprazole | 1 | 2020 | 5 | 0.200 |
Why?
|
| Disease Transmission, Infectious | 2 | 2012 | 57 | 0.200 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2000 | 25 | 0.190 |
Why?
|
| Hand Disinfection | 2 | 2011 | 17 | 0.190 |
Why?
|
| Heart Arrest | 2 | 2014 | 265 | 0.190 |
Why?
|
| Calibration | 2 | 2018 | 99 | 0.190 |
Why?
|
| Aedes | 2 | 2012 | 8 | 0.190 |
Why?
|
| Drug Therapy, Combination | 3 | 2013 | 895 | 0.190 |
Why?
|
| Brain Mapping | 1 | 2004 | 549 | 0.190 |
Why?
|
| Internship and Residency | 3 | 2023 | 1010 | 0.190 |
Why?
|
| Nitrous Oxide | 1 | 2021 | 107 | 0.190 |
Why?
|
| Clinical Deterioration | 1 | 2020 | 19 | 0.190 |
Why?
|
| Mentoring | 1 | 2021 | 30 | 0.190 |
Why?
|
| Psychotropic Drugs | 5 | 2012 | 75 | 0.190 |
Why?
|
| Lithium | 6 | 1987 | 59 | 0.190 |
Why?
|
| Vitamin D | 1 | 2022 | 261 | 0.180 |
Why?
|
| Health Risk Behaviors | 1 | 2020 | 5 | 0.180 |
Why?
|
| Influenza B virus | 2 | 2018 | 29 | 0.180 |
Why?
|
| Attitude of Health Personnel | 2 | 2012 | 636 | 0.180 |
Why?
|
| Phylogeny | 7 | 2017 | 1137 | 0.180 |
Why?
|
| Combined Modality Therapy | 8 | 2013 | 1686 | 0.180 |
Why?
|
| Schools | 5 | 2013 | 71 | 0.180 |
Why?
|
| User-Computer Interface | 1 | 2021 | 185 | 0.180 |
Why?
|
| Government Regulation | 1 | 2000 | 49 | 0.180 |
Why?
|
| Psychopathology | 1 | 2019 | 29 | 0.180 |
Why?
|
| Drug Labeling | 2 | 2011 | 41 | 0.180 |
Why?
|
| Perinatal Care | 1 | 2019 | 18 | 0.170 |
Why?
|
| Immunization Schedule | 2 | 2016 | 21 | 0.170 |
Why?
|
| Students | 4 | 2023 | 147 | 0.170 |
Why?
|
| Teaching | 1 | 2020 | 147 | 0.170 |
Why?
|
| Text Messaging | 1 | 2019 | 27 | 0.170 |
Why?
|
| Smartphone | 1 | 2019 | 36 | 0.170 |
Why?
|
| Patients | 2 | 2010 | 100 | 0.170 |
Why?
|
| Immunoglobulin G | 4 | 2013 | 456 | 0.170 |
Why?
|
| Self-Assessment | 2 | 2021 | 47 | 0.170 |
Why?
|
| Latin America | 1 | 2018 | 14 | 0.160 |
Why?
|
| Socioeconomic Factors | 4 | 2014 | 567 | 0.160 |
Why?
|
| Alcoholism | 7 | 1993 | 172 | 0.160 |
Why?
|
| Wilderness Medicine | 1 | 2018 | 1 | 0.160 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 177 | 0.160 |
Why?
|
| Culicidae | 2 | 2015 | 8 | 0.160 |
Why?
|
| Psychophysiologic Disorders | 1 | 1998 | 7 | 0.160 |
Why?
|
| Fever | 3 | 2018 | 125 | 0.160 |
Why?
|
| Mobile Applications | 1 | 2019 | 63 | 0.160 |
Why?
|
| House Calls | 1 | 1997 | 9 | 0.160 |
Why?
|
| Somatoform Disorders | 1 | 1998 | 29 | 0.160 |
Why?
|
| Patient Compliance | 3 | 2017 | 228 | 0.160 |
Why?
|
| Medial Forebrain Bundle | 1 | 2017 | 1 | 0.160 |
Why?
|
| Personal Satisfaction | 1 | 2018 | 62 | 0.160 |
Why?
|
| Atomoxetine Hydrochloride | 1 | 2017 | 5 | 0.150 |
Why?
|
| Cognition Disorders | 2 | 2018 | 236 | 0.150 |
Why?
|
| Health Resources | 1 | 2018 | 76 | 0.150 |
Why?
|
| Analgesia | 1 | 2018 | 57 | 0.150 |
Why?
|
| Survival Analysis | 5 | 2019 | 1538 | 0.150 |
Why?
|
| Drug Industry | 1 | 1998 | 54 | 0.150 |
Why?
|
| Family Characteristics | 3 | 2014 | 48 | 0.150 |
Why?
|
| Animals | 15 | 2015 | 26590 | 0.150 |
Why?
|
| Fatigue | 1 | 2018 | 174 | 0.150 |
Why?
|
| Hospital Rapid Response Team | 2 | 2014 | 27 | 0.150 |
Why?
|
| Attitude to Health | 2 | 1998 | 220 | 0.150 |
Why?
|
| Clinical Coding | 1 | 2017 | 23 | 0.150 |
Why?
|
| Predictive Value of Tests | 5 | 2010 | 1673 | 0.150 |
Why?
|
| HIV Infections | 3 | 2015 | 772 | 0.150 |
Why?
|
| Photoplethysmography | 1 | 2016 | 2 | 0.150 |
Why?
|
| Population Density | 1 | 2017 | 60 | 0.150 |
Why?
|
| Antidepressive Agents, Tricyclic | 3 | 2007 | 19 | 0.150 |
Why?
|
| Decision Trees | 1 | 2016 | 63 | 0.150 |
Why?
|
| Immunologic Memory | 2 | 2019 | 152 | 0.150 |
Why?
|
| Influenza A Virus, H9N2 Subtype | 2 | 2013 | 8 | 0.140 |
Why?
|
| Patient Transfer | 2 | 2014 | 91 | 0.140 |
Why?
|
| Spinal Cord Injuries | 1 | 2017 | 54 | 0.140 |
Why?
|
| Seroepidemiologic Studies | 5 | 2015 | 55 | 0.140 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2014 | 37 | 0.140 |
Why?
|
| Program Evaluation | 3 | 2020 | 297 | 0.140 |
Why?
|
| Markov Chains | 2 | 2014 | 125 | 0.140 |
Why?
|
| Cross Reactions | 5 | 2013 | 106 | 0.140 |
Why?
|
| Influenza A Virus, H5N1 Subtype | 2 | 2013 | 63 | 0.140 |
Why?
|
| Fluid Therapy | 1 | 2016 | 50 | 0.140 |
Why?
|
| Diffusion of Innovation | 2 | 2015 | 71 | 0.140 |
Why?
|
| Drug Costs | 1 | 1996 | 62 | 0.140 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2015 | 14 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2016 | 1375 | 0.130 |
Why?
|
| Vagus Nerve | 1 | 2015 | 45 | 0.130 |
Why?
|
| Blood Transfusion | 1 | 2016 | 157 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2015 | 1961 | 0.130 |
Why?
|
| Sleep Wake Disorders | 1 | 2017 | 115 | 0.130 |
Why?
|
| Seizures | 1 | 2018 | 297 | 0.130 |
Why?
|
| Unemployment | 2 | 2012 | 8 | 0.130 |
Why?
|
| Dexamethasone | 3 | 1987 | 326 | 0.130 |
Why?
|
| Prescription Drugs | 2 | 2012 | 36 | 0.130 |
Why?
|
| Genes, MHC Class I | 1 | 2015 | 48 | 0.130 |
Why?
|
| Nerve Block | 1 | 2015 | 51 | 0.130 |
Why?
|
| Chicago | 4 | 2022 | 1380 | 0.130 |
Why?
|
| Health Services Research | 1 | 2015 | 136 | 0.130 |
Why?
|
| Hemagglutination Inhibition Tests | 4 | 2015 | 37 | 0.130 |
Why?
|
| Telemedicine | 1 | 2017 | 169 | 0.120 |
Why?
|
| Numerical Analysis, Computer-Assisted | 1 | 2014 | 33 | 0.120 |
Why?
|
| Probability | 3 | 2009 | 355 | 0.120 |
Why?
|
| Autism Spectrum Disorder | 1 | 2015 | 76 | 0.120 |
Why?
|
| Hospital Administration | 1 | 2014 | 26 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 364 | 0.120 |
Why?
|
| Prognosis | 5 | 2021 | 3680 | 0.120 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2013 | 4 | 0.120 |
Why?
|
| HLA-B Antigens | 1 | 2014 | 35 | 0.120 |
Why?
|
| Urban Population | 2 | 2012 | 214 | 0.120 |
Why?
|
| Varenicline | 1 | 2013 | 13 | 0.120 |
Why?
|
| Diabetes, Gestational | 1 | 2014 | 39 | 0.120 |
Why?
|
| Cardiovascular Agents | 1 | 2014 | 56 | 0.120 |
Why?
|
| Rabies virus | 2 | 2004 | 5 | 0.120 |
Why?
|
| Congenital Abnormalities | 1 | 2014 | 63 | 0.120 |
Why?
|
| Bupropion | 1 | 2013 | 21 | 0.120 |
Why?
|
| Lung Diseases | 1 | 2016 | 263 | 0.120 |
Why?
|
| Psychomotor Agitation | 1 | 2013 | 26 | 0.120 |
Why?
|
| Influenza A virus | 2 | 2011 | 169 | 0.120 |
Why?
|
| Reassortant Viruses | 1 | 2013 | 23 | 0.120 |
Why?
|
| Immunity, Humoral | 1 | 2014 | 67 | 0.120 |
Why?
|
| Cross Protection | 1 | 2013 | 8 | 0.120 |
Why?
|
| Weight Loss | 1 | 2015 | 229 | 0.120 |
Why?
|
| Swine Diseases | 1 | 2013 | 14 | 0.120 |
Why?
|
| Computing Methodologies | 1 | 2013 | 9 | 0.120 |
Why?
|
| Confidence Intervals | 2 | 2010 | 229 | 0.120 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2014 | 58 | 0.120 |
Why?
|
| Monte Carlo Method | 1 | 2014 | 185 | 0.120 |
Why?
|
| Length of Stay | 3 | 2008 | 704 | 0.120 |
Why?
|
| Smoking | 2 | 2017 | 609 | 0.120 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2014 | 89 | 0.110 |
Why?
|
| Inflammation | 1 | 2019 | 923 | 0.110 |
Why?
|
| Models, Immunological | 1 | 2013 | 80 | 0.110 |
Why?
|
| Tranquilizing Agents | 1 | 2012 | 7 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 3 | 2013 | 853 | 0.110 |
Why?
|
| Inpatients | 2 | 2014 | 298 | 0.110 |
Why?
|
| Health Plan Implementation | 1 | 2013 | 56 | 0.110 |
Why?
|
| Coronary Disease | 1 | 2014 | 261 | 0.110 |
Why?
|
| Emigration and Immigration | 1 | 2013 | 48 | 0.110 |
Why?
|
| Bhutan | 1 | 2012 | 2 | 0.110 |
Why?
|
| Off-Label Use | 1 | 2012 | 16 | 0.110 |
Why?
|
| Molecular Epidemiology | 2 | 2013 | 53 | 0.110 |
Why?
|
| Vaccines, Attenuated | 3 | 2019 | 51 | 0.110 |
Why?
|
| Random Allocation | 4 | 1997 | 332 | 0.110 |
Why?
|
| Endemic Diseases | 2 | 2019 | 4 | 0.110 |
Why?
|
| Marketing | 1 | 2012 | 23 | 0.110 |
Why?
|
| Double-Blind Method | 5 | 2021 | 1824 | 0.110 |
Why?
|
| Factor Analysis, Statistical | 2 | 2008 | 111 | 0.110 |
Why?
|
| New York City | 1 | 2012 | 59 | 0.110 |
Why?
|
| Health Promotion | 2 | 2013 | 160 | 0.110 |
Why?
|
| Obesity, Morbid | 1 | 2015 | 225 | 0.110 |
Why?
|
| Organizational Culture | 1 | 2012 | 33 | 0.110 |
Why?
|
| Pharmacovigilance | 1 | 2012 | 2 | 0.110 |
Why?
|
| Adrenergic Agents | 1 | 2012 | 6 | 0.110 |
Why?
|
| Environment | 1 | 2014 | 219 | 0.110 |
Why?
|
| Nausea | 1 | 2013 | 175 | 0.110 |
Why?
|
| Health Services Accessibility | 2 | 2006 | 394 | 0.110 |
Why?
|
| Morbidity | 2 | 2022 | 148 | 0.110 |
Why?
|
| Risk Reduction Behavior | 2 | 2013 | 98 | 0.110 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 577 | 0.100 |
Why?
|
| Homosexuality, Male | 1 | 2015 | 298 | 0.100 |
Why?
|
| Viremia | 1 | 2012 | 55 | 0.100 |
Why?
|
| Child Health Services | 2 | 2004 | 49 | 0.100 |
Why?
|
| Occupational Exposure | 1 | 2012 | 80 | 0.100 |
Why?
|
| Poultry Diseases | 1 | 2011 | 13 | 0.100 |
Why?
|
| Hantavirus Infections | 1 | 2011 | 2 | 0.100 |
Why?
|
| Histamine H1 Antagonists, Non-Sedating | 1 | 2011 | 13 | 0.100 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 73 | 0.100 |
Why?
|
| Shrews | 1 | 2011 | 5 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 196 | 0.100 |
Why?
|
| Phenylcarbamates | 1 | 2011 | 6 | 0.100 |
Why?
|
| Tosyl Compounds | 1 | 2011 | 15 | 0.100 |
Why?
|
| Molecular Sequence Data | 3 | 2013 | 3030 | 0.100 |
Why?
|
| Cyclopropanes | 1 | 2011 | 25 | 0.100 |
Why?
|
| Aging | 1 | 2016 | 691 | 0.100 |
Why?
|
| Norepinephrine | 3 | 1988 | 167 | 0.100 |
Why?
|
| Transcriptome | 1 | 2016 | 580 | 0.100 |
Why?
|
| Orthomyxoviridae Infections | 1 | 2011 | 46 | 0.100 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2012 | 76 | 0.100 |
Why?
|
| Health Care Surveys | 2 | 2012 | 278 | 0.100 |
Why?
|
| Hydroxyindoleacetic Acid | 3 | 1990 | 27 | 0.100 |
Why?
|
| Acetates | 1 | 2011 | 66 | 0.100 |
Why?
|
| Pollen | 1 | 2011 | 80 | 0.100 |
Why?
|
| Antibodies, Bacterial | 1 | 2011 | 95 | 0.100 |
Why?
|
| Sulfides | 1 | 2011 | 68 | 0.100 |
Why?
|
| Panic Disorder | 2 | 2008 | 22 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2012 | 118 | 0.100 |
Why?
|
| Registries | 2 | 2019 | 703 | 0.100 |
Why?
|
| Methoxyhydroxyphenylglycol | 4 | 1988 | 18 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2014 | 374 | 0.100 |
Why?
|
| Vital Signs | 2 | 2022 | 38 | 0.100 |
Why?
|
| Hydroxyurea | 1 | 2011 | 239 | 0.100 |
Why?
|
| Proportional Hazards Models | 3 | 2009 | 860 | 0.100 |
Why?
|
| Conduct Disorder | 1 | 2011 | 62 | 0.100 |
Why?
|
| Epidemiological Monitoring | 3 | 2017 | 39 | 0.100 |
Why?
|
| Smoking Prevention | 3 | 1996 | 43 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2012 | 312 | 0.100 |
Why?
|
| Animal Structures | 1 | 2010 | 22 | 0.100 |
Why?
|
| Environmental Microbiology | 1 | 2010 | 22 | 0.100 |
Why?
|
| Masks | 1 | 2011 | 29 | 0.100 |
Why?
|
| Allergens | 1 | 2011 | 179 | 0.100 |
Why?
|
| Cities | 1 | 2010 | 40 | 0.090 |
Why?
|
| Quinolines | 1 | 2011 | 95 | 0.090 |
Why?
|
| Virology | 1 | 2010 | 9 | 0.090 |
Why?
|
| Seasons | 1 | 2011 | 223 | 0.090 |
Why?
|
| Pharynx | 1 | 2010 | 45 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 1921 | 0.090 |
Why?
|
| Antibody-Dependent Enhancement | 1 | 2009 | 1 | 0.090 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2014 | 558 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2011 | 263 | 0.090 |
Why?
|
| Medication Errors | 1 | 2010 | 39 | 0.090 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2010 | 102 | 0.090 |
Why?
|
| Data Collection | 3 | 2015 | 372 | 0.090 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2010 | 39 | 0.090 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2013 | 246 | 0.090 |
Why?
|
| Analysis of Variance | 4 | 2012 | 912 | 0.090 |
Why?
|
| Models, Biological | 3 | 2014 | 1749 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2015 | 879 | 0.090 |
Why?
|
| Aggression | 1 | 2013 | 320 | 0.090 |
Why?
|
| Nose | 1 | 2010 | 94 | 0.090 |
Why?
|
| Speech | 1 | 2010 | 84 | 0.090 |
Why?
|
| Indoles | 1 | 2011 | 318 | 0.090 |
Why?
|
| Debrisoquin | 1 | 1989 | 1 | 0.090 |
Why?
|
| Levorphanol | 1 | 1989 | 3 | 0.090 |
Why?
|
| Infection Control | 1 | 2010 | 115 | 0.090 |
Why?
|
| Imipramine | 2 | 1995 | 16 | 0.090 |
Why?
|
| Postpartum Period | 2 | 2021 | 135 | 0.090 |
Why?
|
| Dextromethorphan | 1 | 1989 | 11 | 0.090 |
Why?
|
| Sulfonamides | 1 | 2011 | 300 | 0.090 |
Why?
|
| Personality Assessment | 4 | 2010 | 98 | 0.080 |
Why?
|
| Viral Envelope Proteins | 3 | 2015 | 94 | 0.080 |
Why?
|
| Epilepsy | 1 | 2013 | 397 | 0.080 |
Why?
|
| Observer Variation | 1 | 2010 | 603 | 0.080 |
Why?
|
| Isoquinolines | 1 | 1989 | 72 | 0.080 |
Why?
|
| Placebos | 5 | 2014 | 218 | 0.080 |
Why?
|
| Prostatectomy | 2 | 2011 | 471 | 0.080 |
Why?
|
| Prostate-Specific Antigen | 1 | 2011 | 353 | 0.080 |
Why?
|
| Picornaviridae Infections | 1 | 2008 | 7 | 0.080 |
Why?
|
| Adolescent Health Services | 1 | 2008 | 11 | 0.080 |
Why?
|
| Prostatic Neoplasms | 2 | 2011 | 1721 | 0.080 |
Why?
|
| Clinical Trials as Topic | 6 | 2011 | 1169 | 0.080 |
Why?
|
| Agoraphobia | 1 | 2008 | 2 | 0.080 |
Why?
|
| Rhinovirus | 1 | 2008 | 25 | 0.080 |
Why?
|
| Phobic Disorders | 1 | 2008 | 13 | 0.080 |
Why?
|
| Schizophrenic Psychology | 3 | 1993 | 129 | 0.080 |
Why?
|
| ABO Blood-Group System | 1 | 2008 | 62 | 0.080 |
Why?
|
| Histocompatibility Testing | 1 | 2008 | 154 | 0.080 |
Why?
|
| Health Policy | 2 | 2000 | 180 | 0.080 |
Why?
|
| Leptospirosis | 1 | 2007 | 3 | 0.080 |
Why?
|
| Linear Models | 2 | 2012 | 422 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2022 | 840 | 0.080 |
Why?
|
| European Union | 1 | 2007 | 8 | 0.080 |
Why?
|
| Utilization Review | 2 | 2017 | 21 | 0.080 |
Why?
|
| Netherlands | 1 | 2007 | 19 | 0.080 |
Why?
|
| Monoamine Oxidase | 2 | 1984 | 24 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 144 | 0.080 |
Why?
|
| Epidemiologic Research Design | 1 | 2007 | 22 | 0.080 |
Why?
|
| Psychology | 1 | 2007 | 24 | 0.080 |
Why?
|
| Prostate | 1 | 2011 | 378 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 2231 | 0.080 |
Why?
|
| Respiratory Tract Infections | 1 | 2008 | 105 | 0.080 |
Why?
|
| Homovanillic Acid | 2 | 1988 | 35 | 0.080 |
Why?
|
| Juvenile Delinquency | 1 | 2007 | 27 | 0.080 |
Why?
|
| Risk-Taking | 1 | 2008 | 148 | 0.070 |
Why?
|
| Pleural Effusion | 1 | 2007 | 45 | 0.070 |
Why?
|
| Swine | 3 | 2013 | 555 | 0.070 |
Why?
|
| Diagnosis-Related Groups | 1 | 2006 | 20 | 0.070 |
Why?
|
| Global Health | 1 | 2008 | 193 | 0.070 |
Why?
|
| Glycols | 1 | 1986 | 8 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 724 | 0.070 |
Why?
|
| Spatio-Temporal Analysis | 2 | 2017 | 21 | 0.070 |
Why?
|
| Income | 1 | 2006 | 76 | 0.070 |
Why?
|
| Specialization | 2 | 1997 | 65 | 0.070 |
Why?
|
| Disease | 2 | 1983 | 90 | 0.070 |
Why?
|
| Clinical Competence | 2 | 2023 | 756 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2022 | 584 | 0.070 |
Why?
|
| Early Diagnosis | 2 | 2018 | 132 | 0.070 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2008 | 157 | 0.070 |
Why?
|
| Bias | 2 | 2006 | 127 | 0.070 |
Why?
|
| Certification | 2 | 2023 | 58 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2019 | 220 | 0.060 |
Why?
|
| Survival Rate | 1 | 2009 | 1864 | 0.060 |
Why?
|
| Hospitals | 1 | 2007 | 294 | 0.060 |
Why?
|
| Disease Reservoirs | 1 | 2004 | 22 | 0.060 |
Why?
|
| Child Welfare | 1 | 2004 | 39 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 1195 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2004 | 1037 | 0.060 |
Why?
|
| Bacterial Proteins | 1 | 2010 | 864 | 0.060 |
Why?
|
| Travel | 1 | 2004 | 68 | 0.060 |
Why?
|
| Asthma | 1 | 2012 | 955 | 0.060 |
Why?
|
| Immunoglobulins | 1 | 2004 | 148 | 0.060 |
Why?
|
| Prejudice | 1 | 2004 | 49 | 0.060 |
Why?
|
| Acute Disease | 2 | 2007 | 826 | 0.060 |
Why?
|
| Child Abuse | 1 | 2004 | 78 | 0.060 |
Why?
|
| Dogs | 1 | 2004 | 686 | 0.060 |
Why?
|
| Medicare | 2 | 2017 | 410 | 0.060 |
Why?
|
| Geography | 2 | 2016 | 223 | 0.060 |
Why?
|
| Malpractice | 2 | 1995 | 57 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 4 | 1999 | 274 | 0.060 |
Why?
|
| Persian Gulf Syndrome | 1 | 2003 | 3 | 0.060 |
Why?
|
| Warfare | 1 | 2003 | 10 | 0.060 |
Why?
|
| Social Support | 2 | 2019 | 193 | 0.060 |
Why?
|
| Quality of Health Care | 2 | 2019 | 381 | 0.060 |
Why?
|
| Licensure, Medical | 1 | 2023 | 19 | 0.060 |
Why?
|
| Fissure in Ano | 1 | 2002 | 3 | 0.060 |
Why?
|
| Awareness | 2 | 2021 | 93 | 0.060 |
Why?
|
| Causality | 1 | 2003 | 81 | 0.060 |
Why?
|
| Appointments and Schedules | 1 | 2023 | 53 | 0.060 |
Why?
|
| Influenza in Birds | 2 | 2013 | 31 | 0.050 |
Why?
|
| Nitroglycerin | 1 | 2002 | 22 | 0.050 |
Why?
|
| Motor Vehicles | 1 | 2022 | 18 | 0.050 |
Why?
|
| Laos | 2 | 2015 | 4 | 0.050 |
Why?
|
| Endophenotypes | 1 | 2022 | 17 | 0.050 |
Why?
|
| Japan | 2 | 2007 | 307 | 0.050 |
Why?
|
| Japanese Encephalitis Vaccines | 2 | 2013 | 2 | 0.050 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2022 | 37 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2022 | 71 | 0.050 |
Why?
|
| Age of Onset | 2 | 2001 | 310 | 0.050 |
Why?
|
| Vasodilator Agents | 1 | 2002 | 152 | 0.050 |
Why?
|
| Blood Platelets | 3 | 2010 | 149 | 0.050 |
Why?
|
| Saccades | 1 | 2022 | 69 | 0.050 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2022 | 99 | 0.050 |
Why?
|
| Skin Pigmentation | 1 | 2021 | 40 | 0.050 |
Why?
|
| Case Management | 1 | 2021 | 24 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2003 | 241 | 0.050 |
Why?
|
| National Institute of Mental Health (U.S.) | 2 | 2007 | 22 | 0.050 |
Why?
|
| Policy | 1 | 2021 | 34 | 0.050 |
Why?
|
| Drug Delivery Systems | 1 | 2002 | 178 | 0.050 |
Why?
|
| Educational Measurement | 1 | 2023 | 226 | 0.050 |
Why?
|
| Occupational Stress | 1 | 2020 | 2 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2004 | 405 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2001 | 156 | 0.050 |
Why?
|
| Injections | 1 | 2020 | 109 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 116 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 916 | 0.050 |
Why?
|
| Child, Hospitalized | 1 | 2020 | 33 | 0.050 |
Why?
|
| Sampling Studies | 2 | 1997 | 70 | 0.050 |
Why?
|
| World Health Organization | 2 | 2010 | 103 | 0.050 |
Why?
|
| Immunoassay | 2 | 2010 | 92 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2021 | 122 | 0.040 |
Why?
|
| Patient Acuity | 1 | 2019 | 33 | 0.040 |
Why?
|
| Health Planning | 1 | 1999 | 17 | 0.040 |
Why?
|
| Triazolam | 1 | 1999 | 5 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 31 | 0.040 |
Why?
|
| Hydrocortisone | 3 | 1987 | 298 | 0.040 |
Why?
|
| Emotions | 1 | 1983 | 341 | 0.040 |
Why?
|
| Adjustment Disorders | 1 | 1998 | 6 | 0.040 |
Why?
|
| Manuals as Topic | 1 | 1998 | 9 | 0.040 |
Why?
|
| Kinetics | 2 | 2015 | 1513 | 0.040 |
Why?
|
| Affective Symptoms | 2 | 2004 | 47 | 0.040 |
Why?
|
| Pharmacogenetics | 2 | 2015 | 434 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2022 | 492 | 0.040 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2018 | 16 | 0.040 |
Why?
|
| Television | 1 | 1997 | 29 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 193 | 0.040 |
Why?
|
| Internal-External Control | 1 | 1998 | 44 | 0.040 |
Why?
|
| Disease Progression | 2 | 2016 | 1532 | 0.040 |
Why?
|
| Hospitals, Urban | 1 | 2018 | 54 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 1999 | 125 | 0.040 |
Why?
|
| Serotonin | 2 | 2010 | 218 | 0.040 |
Why?
|
| Electroencephalography | 1 | 2022 | 709 | 0.040 |
Why?
|
| Professional Practice | 1 | 1997 | 46 | 0.040 |
Why?
|
| Calcinosis | 1 | 1999 | 224 | 0.040 |
Why?
|
| Conflict of Interest | 1 | 1998 | 67 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 1999 | 177 | 0.040 |
Why?
|
| Platelet Count | 2 | 2010 | 92 | 0.040 |
Why?
|
| Mosquito Vectors | 1 | 2017 | 5 | 0.040 |
Why?
|
| Reference Values | 3 | 2009 | 674 | 0.040 |
Why?
|
| Breath Tests | 2 | 1988 | 55 | 0.040 |
Why?
|
| Intubation, Gastrointestinal | 1 | 1997 | 31 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 751 | 0.040 |
Why?
|
| Pneumoconiosis | 1 | 1996 | 5 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 69 | 0.040 |
Why?
|
| Medicine | 1 | 1997 | 90 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2000 | 349 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2019 | 464 | 0.040 |
Why?
|
| Enteral Nutrition | 1 | 1997 | 102 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 69 | 0.040 |
Why?
|
| Health Behavior | 1 | 1997 | 183 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2016 | 30 | 0.030 |
Why?
|
| Video Recording | 1 | 1997 | 190 | 0.030 |
Why?
|
| Patient Admission | 1 | 1996 | 112 | 0.030 |
Why?
|
| Injections, Intradermal | 1 | 2015 | 19 | 0.030 |
Why?
|
| Asia, Southeastern | 1 | 2015 | 16 | 0.030 |
Why?
|
| Vaccines, Inactivated | 1 | 2015 | 29 | 0.030 |
Why?
|
| Serogroup | 1 | 2015 | 9 | 0.030 |
Why?
|
| Immune Sera | 1 | 2015 | 52 | 0.030 |
Why?
|
| Insurance, Liability | 1 | 1995 | 10 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2015 | 62 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 455 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 1997 | 153 | 0.030 |
Why?
|
| Legislation, Medical | 1 | 1995 | 9 | 0.030 |
Why?
|
| Hospitals, Military | 1 | 2015 | 3 | 0.030 |
Why?
|
| Heartburn | 1 | 2015 | 9 | 0.030 |
Why?
|
| Tropical Climate | 1 | 2015 | 31 | 0.030 |
Why?
|
| Dyspepsia | 1 | 2015 | 10 | 0.030 |
Why?
|
| Risk Management | 1 | 1995 | 43 | 0.030 |
Why?
|
| Climate | 1 | 2015 | 50 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 217 | 0.030 |
Why?
|
| Psychology, Adolescent | 1 | 2015 | 29 | 0.030 |
Why?
|
| Electrodes | 1 | 2015 | 78 | 0.030 |
Why?
|
| Pediatrics | 1 | 1999 | 344 | 0.030 |
Why?
|
| Dimensional Measurement Accuracy | 1 | 2014 | 4 | 0.030 |
Why?
|
| Mathematics | 1 | 1994 | 190 | 0.030 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 220 | 0.030 |
Why?
|
| Specialties, Surgical | 1 | 1995 | 64 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 1 | 2014 | 28 | 0.030 |
Why?
|
| Critical Care | 2 | 2014 | 370 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2015 | 103 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 1997 | 351 | 0.030 |
Why?
|
| Coronary Artery Disease | 1 | 1999 | 350 | 0.030 |
Why?
|
| Molecular Typing | 1 | 2014 | 17 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2015 | 256 | 0.030 |
Why?
|
| Pursuit, Smooth | 2 | 1984 | 31 | 0.030 |
Why?
|
| Alcohol Drinking | 2 | 2007 | 267 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 2015 | 137 | 0.030 |
Why?
|
| Erythrocytes | 3 | 1984 | 255 | 0.030 |
Why?
|
| Basic Reproduction Number | 1 | 2013 | 6 | 0.030 |
Why?
|
| Eye Movements | 2 | 1985 | 119 | 0.030 |
Why?
|
| Hawaii | 1 | 2013 | 26 | 0.030 |
Why?
|
| Research | 2 | 1985 | 253 | 0.030 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2013 | 13 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 1993 | 15 | 0.030 |
Why?
|
| Economic Recession | 1 | 2012 | 5 | 0.030 |
Why?
|
| Cell Phone | 1 | 2013 | 37 | 0.030 |
Why?
|
| Sus scrofa | 1 | 2012 | 45 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2014 | 278 | 0.030 |
Why?
|
| Health Surveys | 1 | 2013 | 239 | 0.030 |
Why?
|
| Receptors, Leukotriene | 1 | 2012 | 10 | 0.030 |
Why?
|
| Clinical Medicine | 1 | 1992 | 34 | 0.030 |
Why?
|
| Temperance | 1 | 1992 | 7 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 268 | 0.030 |
Why?
|
| Survivors | 1 | 2014 | 226 | 0.030 |
Why?
|
| Housing | 1 | 2012 | 42 | 0.030 |
Why?
|
| Forecasting | 1 | 2013 | 305 | 0.030 |
Why?
|
| Death Certificates | 1 | 2011 | 11 | 0.030 |
Why?
|
| Poultry | 1 | 2011 | 22 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2014 | 459 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2014 | 458 | 0.030 |
Why?
|
| Enzyme-Linked Immunospot Assay | 1 | 2011 | 7 | 0.030 |
Why?
|
| Birds | 1 | 2013 | 157 | 0.030 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2011 | 42 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 770 | 0.030 |
Why?
|
| Interview, Psychological | 1 | 2011 | 69 | 0.030 |
Why?
|
| Feces | 1 | 2013 | 319 | 0.030 |
Why?
|
| Cerebral Ventricles | 1 | 1991 | 76 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 41 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2011 | 136 | 0.030 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2011 | 81 | 0.020 |
Why?
|
| Serum | 1 | 2011 | 25 | 0.020 |
Why?
|
| Afghanistan | 1 | 2010 | 2 | 0.020 |
Why?
|
| Nasopharynx | 1 | 2011 | 47 | 0.020 |
Why?
|
| Orthomyxoviridae | 1 | 2011 | 37 | 0.020 |
Why?
|
| Viral Plaque Assay | 1 | 2010 | 19 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2014 | 728 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2010 | 77 | 0.020 |
Why?
|
| Hematocrit | 1 | 2010 | 68 | 0.020 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2011 | 179 | 0.020 |
Why?
|
| Humidity | 1 | 2010 | 89 | 0.020 |
Why?
|
| Nurse Practitioners | 1 | 2010 | 32 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2010 | 73 | 0.020 |
Why?
|
| Philippines | 1 | 2010 | 23 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 303 | 0.020 |
Why?
|
| Irritable Mood | 1 | 2010 | 10 | 0.020 |
Why?
|
| Normetanephrine | 2 | 1988 | 4 | 0.020 |
Why?
|
| Indonesia | 1 | 2010 | 11 | 0.020 |
Why?
|
| Lithium Carbonate | 2 | 1987 | 8 | 0.020 |
Why?
|
| Curriculum | 1 | 1994 | 543 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 928 | 0.020 |
Why?
|
| Pharmacists | 1 | 2010 | 32 | 0.020 |
Why?
|
| Nurses | 1 | 2010 | 40 | 0.020 |
Why?
|
| Hand | 1 | 2010 | 130 | 0.020 |
Why?
|
| Nasal Mucosa | 1 | 2010 | 186 | 0.020 |
Why?
|
| Specimen Handling | 1 | 2010 | 98 | 0.020 |
Why?
|
| Hearing | 1 | 2010 | 59 | 0.020 |
Why?
|
| Evolution, Molecular | 1 | 2015 | 813 | 0.020 |
Why?
|
| Reference Standards | 1 | 2010 | 159 | 0.020 |
Why?
|
| Leukocytes | 1 | 2010 | 202 | 0.020 |
Why?
|
| Hospitals, Pediatric | 1 | 2010 | 107 | 0.020 |
Why?
|
| Behavioral Symptoms | 1 | 2009 | 15 | 0.020 |
Why?
|
| Temperature | 1 | 2010 | 396 | 0.020 |
Why?
|
| Public Health Practice | 1 | 2009 | 11 | 0.020 |
Why?
|
| Patient Readmission | 1 | 1993 | 329 | 0.020 |
Why?
|
| Financing, Government | 1 | 2009 | 23 | 0.020 |
Why?
|
| Auditory Perception | 1 | 2010 | 96 | 0.020 |
Why?
|
| Introns | 1 | 2010 | 289 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1999 | 2601 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2010 | 160 | 0.020 |
Why?
|
| Biogenic Amines | 1 | 1988 | 2 | 0.020 |
Why?
|
| Capsid Proteins | 1 | 2008 | 32 | 0.020 |
Why?
|
| South Africa | 1 | 2008 | 60 | 0.020 |
Why?
|
| Family Relations | 1 | 2008 | 35 | 0.020 |
Why?
|
| Stress, Psychological | 2 | 2003 | 313 | 0.020 |
Why?
|
| Irritants | 1 | 1988 | 4 | 0.020 |
Why?
|
| Preventive Health Services | 1 | 2008 | 37 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2009 | 122 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 1989 | 373 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 1683 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2008 | 292 | 0.020 |
Why?
|
| Serologic Tests | 1 | 2007 | 41 | 0.020 |
Why?
|
| Eye Diseases | 1 | 1988 | 53 | 0.020 |
Why?
|
| Chronic Disease | 2 | 2002 | 973 | 0.020 |
Why?
|
| Gallbladder | 1 | 2007 | 30 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2007 | 308 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2007 | 92 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 334 | 0.020 |
Why?
|
| Ascites | 1 | 2007 | 56 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2015 | 2357 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 1 | 1987 | 64 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 1987 | 81 | 0.020 |
Why?
|
| Vanilmandelic Acid | 1 | 1986 | 4 | 0.020 |
Why?
|
| Viral Proteins | 1 | 2008 | 300 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2271 | 0.020 |
Why?
|
| Neurons | 1 | 2014 | 1547 | 0.020 |
Why?
|
| Computers | 3 | 1994 | 112 | 0.020 |
Why?
|
| ROC Curve | 1 | 2007 | 752 | 0.020 |
Why?
|
| Schizophrenic Language | 1 | 1985 | 2 | 0.020 |
Why?
|
| Child, Abandoned | 1 | 2004 | 1 | 0.020 |
Why?
|
| Foster Home Care | 1 | 2004 | 3 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2007 | 320 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 1985 | 32 | 0.020 |
Why?
|
| Social Adjustment | 1 | 1985 | 46 | 0.020 |
Why?
|
| Recurrence | 3 | 1996 | 1139 | 0.020 |
Why?
|
| Electroconvulsive Therapy | 1 | 1985 | 24 | 0.020 |
Why?
|
| Poverty Areas | 1 | 2004 | 37 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2007 | 695 | 0.020 |
Why?
|
| Lung Neoplasms | 2 | 1988 | 2262 | 0.020 |
Why?
|
| Osteogenesis Imperfecta | 1 | 1984 | 4 | 0.020 |
Why?
|
| Arousal | 1 | 1985 | 170 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 508 | 0.010 |
Why?
|
| Blood Proteins | 1 | 1984 | 144 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2003 | 59 | 0.010 |
Why?
|
| Ointments | 1 | 2002 | 12 | 0.010 |
Why?
|
| Affective Disorders, Psychotic | 1 | 1982 | 16 | 0.010 |
Why?
|
| Play and Playthings | 1 | 2001 | 7 | 0.010 |
Why?
|
| Students, Medical | 1 | 1987 | 385 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2004 | 328 | 0.010 |
Why?
|
| Pain Measurement | 1 | 2002 | 321 | 0.010 |
Why?
|
| Adaptation, Psychological | 1 | 2001 | 157 | 0.010 |
Why?
|
| Ion Channels | 1 | 1982 | 246 | 0.010 |
Why?
|
| Specialty Boards | 1 | 2000 | 24 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 1988 | 1464 | 0.010 |
Why?
|
| Mother-Child Relations | 1 | 1999 | 26 | 0.010 |
Why?
|
| Life Change Events | 1 | 1999 | 48 | 0.010 |
Why?
|
| Professional Staff Committees | 1 | 1999 | 7 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1999 | 141 | 0.010 |
Why?
|
| Mental Health Services | 1 | 1999 | 48 | 0.010 |
Why?
|
| Family | 1 | 1999 | 311 | 0.010 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 2 | 1988 | 40 | 0.010 |
Why?
|
| Patients' Rooms | 1 | 1997 | 14 | 0.010 |
Why?
|
| Oregon | 1 | 1995 | 26 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 1995 | 204 | 0.010 |
Why?
|
| Critical Illness | 1 | 1997 | 294 | 0.010 |
Why?
|
| Calcium | 1 | 1999 | 1156 | 0.010 |
Why?
|
| Marital Status | 1 | 1993 | 40 | 0.010 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 1992 | 22 | 0.010 |
Why?
|
| Normal Distribution | 1 | 1991 | 37 | 0.010 |
Why?
|
| Metanephrine | 1 | 1988 | 4 | 0.010 |
Why?
|
| Epinephrine | 1 | 1988 | 84 | 0.010 |
Why?
|
| Rabbits | 1 | 1988 | 636 | 0.000 |
Why?
|
| Circadian Rhythm | 1 | 1988 | 303 | 0.000 |
Why?
|
| Periodicals as Topic | 1 | 1987 | 168 | 0.000 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 1985 | 6 | 0.000 |
Why?
|
| Ambulatory Care | 1 | 1985 | 181 | 0.000 |
Why?
|
| Erythrocyte Membrane | 1 | 1982 | 60 | 0.000 |
Why?
|
| Sodium | 1 | 1982 | 341 | 0.000 |
Why?
|
| Chromosome Mapping | 1 | 1983 | 1074 | 0.000 |
Why?
|
| Alleles | 1 | 1983 | 1128 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1983 | 819 | 0.000 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 1985 | 1077 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1985 | 1169 | 0.000 |
Why?
|